NZ584729A - Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer - Google Patents

Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer

Info

Publication number
NZ584729A
NZ584729A NZ584729A NZ58472908A NZ584729A NZ 584729 A NZ584729 A NZ 584729A NZ 584729 A NZ584729 A NZ 584729A NZ 58472908 A NZ58472908 A NZ 58472908A NZ 584729 A NZ584729 A NZ 584729A
Authority
NZ
New Zealand
Prior art keywords
nilvadipine
animal
microgliosis
amyloid
pharmaceutical composition
Prior art date
Application number
NZ584729A
Other languages
English (en)
Inventor
Michael J Mullan
Daniel Paris
Robert A Ivey
Original Assignee
Alzheimer S Inst Of America Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alzheimer S Inst Of America Inc filed Critical Alzheimer S Inst Of America Inc
Publication of NZ584729A publication Critical patent/NZ584729A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
NZ584729A 2007-10-05 2008-10-03 Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer NZ584729A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97795307P 2007-10-05 2007-10-05
US4610908P 2008-04-18 2008-04-18
PCT/US2008/078786 WO2009046323A1 (en) 2007-10-05 2008-10-03 Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer

Publications (1)

Publication Number Publication Date
NZ584729A true NZ584729A (en) 2012-12-21

Family

ID=40523447

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ584729A NZ584729A (en) 2007-10-05 2008-10-03 Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer

Country Status (16)

Country Link
US (2) US8236346B2 (enExample)
EP (1) EP2214666B1 (enExample)
JP (1) JP5411145B2 (enExample)
KR (1) KR101417200B1 (enExample)
CN (1) CN101883564B (enExample)
AU (1) AU2008308519B2 (enExample)
BR (1) BRPI0817516A2 (enExample)
CA (1) CA2701620C (enExample)
DK (1) DK2214666T3 (enExample)
ES (1) ES2449594T3 (enExample)
MX (1) MX2010003669A (enExample)
NZ (1) NZ584729A (enExample)
PL (1) PL2214666T3 (enExample)
RU (1) RU2490014C2 (enExample)
TW (1) TWI500422B (enExample)
WO (1) WO2009046323A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140286910A1 (en) * 2013-03-19 2014-09-25 Nikolai Tankovich Stem cells and methods incorporating environmental factors as a means for enhancing stem cell proliferation and plasticity
CN112826794B (zh) 2019-11-06 2022-02-11 上海交通大学医学院 一种靶向修复神经血管病变的纳米复合物及其制备与应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338322A (en) * 1975-07-02 1982-07-06 Fujisawa Pharmaceutical Co., Ltd. 1,4-Dihydropyridine derivatives, pharmaceutical compositions containing same and methods of effecting vasodilation using same
JPS6038322A (ja) * 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固形製剤
JPS61129140A (ja) 1984-11-27 1986-06-17 Nitto Electric Ind Co Ltd 医薬組成物
GB8431119D0 (en) * 1984-12-10 1985-01-16 Fujisawa Pharmaceutical Co Anti-arteriosclerotic composition
US4940556A (en) 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
DE3877630T2 (de) 1987-06-12 1993-06-03 American Cyanamid Co Transkutane verabreichung von pharmazeutika.
US5114946A (en) * 1987-06-12 1992-05-19 American Cyanamid Company Transdermal delivery of pharmaceuticals
US5001139A (en) * 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5045553A (en) * 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
US4820720A (en) * 1987-08-24 1989-04-11 Alza Corporation Transdermal drug composition with dual permeation enhancers
US5508413A (en) * 1987-08-27 1996-04-16 Fujisawa Pharmaceutical Co., Ltd. (+)-5-isopropyl 3-methyl 2-cyano-6 methyl-4-(3-nitrophenyl)-1, 4-dihydropyridine-3, 5-dicarboxylate
US5160734A (en) * 1987-11-25 1992-11-03 American Cyanamid Company Sustained release delivery system for substituted dihydropyridine calcium channel blockers
EP0317780B1 (en) 1987-11-25 1992-05-20 American Cyanamid Company Sustained (controlled) release delivery system for substituted dihydropyridine calcium channel blockers
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
JP2718105B2 (ja) 1988-10-27 1998-02-25 藤沢薬品工業株式会社 （＋）−２−シアノ−６−メチル−４−（３−ニトロフェニル）−１，４−ジヒドロピリジン−３，５−ジカルボン酸５−イソプロピル３−メチルの光安定性結晶
JP3479532B2 (ja) * 1989-03-31 2003-12-15 ザ・チルドレンズ・メディカル・センター・コーポレーション エイズの痴呆症、脊髄障害および失明の治療
JPH0381262A (ja) 1989-08-23 1991-04-05 Yamanouchi Pharmaceut Co Ltd ジヒドロピリジン系カルシウム拮抗薬の光学活性体の製造法
JP2867462B2 (ja) 1989-09-12 1999-03-08 藤沢薬品工業株式会社 経皮吸収用製剤
JP2920956B2 (ja) 1989-10-06 1999-07-19 藤沢薬品工業株式会社 ニルバジピン含有持続性錠剤
US5258393A (en) * 1990-02-21 1993-11-02 Fujisawa Pharmaceutical Co., Ltd. Use of a dihydropyridine compound for improving inner ear microcirculation
WO1992003137A1 (en) 1990-08-23 1992-03-05 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy, peripheral neuropathy, and vision loss
WO1993005770A1 (fr) 1991-09-20 1993-04-01 Fujisawa Pharmaceutical Co., Ltd. Preparation a longue duree d'action
JPH05139974A (ja) 1991-11-26 1993-06-08 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固体分散体の製造法
US5834496A (en) * 1991-12-02 1998-11-10 Sepracor, Inc. Methods for treating hypertension using optically pure S(-) felodipine
DE4141646A1 (de) 1991-12-17 1993-06-24 Klinge Co Chem Pharm Fab Arzneimittelkombination mit synergistischer wirkung, verfahren zu seiner herstellung und seine verwendung
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
DE4229805A1 (de) 1992-09-07 1994-03-24 Werner E G Prof Dr Mueller Kalzium-Kanal-Antagonisten oder deren Derivate zur Herstellung eines Arzneimittels zur Bekämpfung von Erkrankungen, die durch Prion-Proteine oder Prion-analoge Proteine ausgelöst werden
CA2125251C (en) 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
ATE204163T1 (de) * 1993-06-30 2001-09-15 Fujisawa Pharmaceutical Co Verkapselter arzneistoff
US6334997B1 (en) * 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
JP3541389B2 (ja) * 1996-04-26 2004-07-07 藤沢薬品工業株式会社 ジヒドロピリジン化合物を含有する眼組織末梢循環改善剤
US6271259B1 (en) * 1996-05-07 2001-08-07 Ito En, Ltd. Method for improving the brain function, inhibiting glutamate excitotoxicity and rescuing from neuronal death
KR100222306B1 (ko) 1996-11-20 1999-10-01 이병언 닐바디핀 속효성 고형제제 및 이의 제조방법
US6541479B1 (en) * 1997-12-02 2003-04-01 Massachusetts College Of Pharmacy Calcium channel blockers
EP1085863A4 (en) 1998-06-08 2001-03-28 Advanced Medicine Inc NEW MEDICINES FOR THE TREATMENT OF FAULTS CAUSED BY CALCIUM CHANNELS AND THEIR USE
WO1999064045A1 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Novel therapeutic agents for membrane transporters
SI1096932T1 (sl) 1998-07-10 2008-04-30 Novartis Pharma Ag Antihipertenzivna kombinacija valsartana in zaviralca kalcijevih kanalov
EP1260232A1 (en) 2000-03-03 2002-11-27 Fujisawa Pharmaceutical Co., Ltd. Remedies for malignant tumor-concomitant neurosis and azoor or analogous diseases thereof
BR0109991A (pt) 2000-04-11 2003-05-27 Sankyo Co Composição farmacêutica
JP2001335483A (ja) 2000-05-30 2001-12-04 Nichiko Pharmaceutical Co Ltd ニルバジピン含有製剤
CA2415826A1 (en) * 2000-07-27 2002-02-07 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
JP3968687B2 (ja) 2000-09-13 2007-08-29 東和薬品株式会社 易吸収性ニルバジピン錠
JP3470096B2 (ja) 2000-09-19 2003-11-25 沢井製薬株式会社 ニルバジピン含有易溶性固形製剤およびその製造法
CA2431074A1 (en) * 2000-12-19 2002-06-27 Merck Patent Gesellschaft Mit Beschraenkter Haftung Pharmaceutical formulation comprising thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (1)
CN1481244A (zh) * 2000-12-19 2004-03-10 Ĭ��ר���ɷ����޹�˾ 含有吡唑并[4,3-d]嘧啶和抗血栓形成剂、钙拮抗剂、前列腺素或前列腺素衍生物的药物制剂
US7083642B2 (en) * 2000-12-22 2006-08-01 Avantec Vascular Corporation Delivery of therapeutic capable agents
CA2333494A1 (en) * 2001-02-01 2002-08-01 Vasogen Ireland Limited Blood brain barrier modulation
EP1392287B8 (en) 2001-05-25 2007-01-10 Schering Corporation Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease
EP1426051B1 (en) * 2001-09-11 2008-07-16 Asahi Kasei Pharma Corporation Medicinal composition for prevention of or treatment for cerebrovascular disorder
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
TW200306799A (en) 2002-05-17 2003-12-01 Novartis Ag Combination of organic compounds
AU2003298514A1 (en) 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
ES2369216T3 (es) 2002-05-17 2011-11-28 Novartis Pharma Ag Composición farmacéutica que comprende un inhibidor de renina, un bloqueador del canal de calcio y un diurético.
JP2003146878A (ja) 2002-11-22 2003-05-21 Sawai Pharmaceutical Co Ltd ニルバジピン含有易溶性固形製剤およびその製造法
EA012325B1 (ru) 2002-12-24 2009-08-28 Беллус Хелс (Интернэшнл) Лимитед Терапевтические составы для лечения болезней, связанных с наличием бета-амилоида
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
CN100444840C (zh) * 2003-05-15 2008-12-24 罗斯坎普研究有限公司 减少淀粉样沉积、淀粉样神经毒性和小胶质增生的药物
JP2004002460A (ja) 2003-07-29 2004-01-08 Towa Yakuhin Kk 易吸収性ニルバジピン錠の製造法
WO2009046338A1 (en) * 2007-10-05 2009-04-09 Roskamp Research Llc Method for increasing cerebral blood flow with (+)-nilvadipine enantiomer

Also Published As

Publication number Publication date
RU2010117634A (ru) 2011-11-10
MX2010003669A (es) 2010-11-25
US8236346B2 (en) 2012-08-07
DK2214666T3 (da) 2014-01-27
US20090092667A1 (en) 2009-04-09
KR20100067683A (ko) 2010-06-21
US8236347B2 (en) 2012-08-07
JP2010540661A (ja) 2010-12-24
TW200920364A (en) 2009-05-16
EP2214666A4 (en) 2010-12-08
AU2008308519A1 (en) 2009-04-09
TWI500422B (zh) 2015-09-21
EP2214666A1 (en) 2010-08-11
AU2008308519A2 (en) 2010-04-29
US20100183711A1 (en) 2010-07-22
CN101883564B (zh) 2013-10-16
PL2214666T3 (pl) 2014-06-30
WO2009046323A1 (en) 2009-04-09
KR101417200B1 (ko) 2014-08-01
CN101883564A (zh) 2010-11-10
CA2701620A1 (en) 2009-04-09
CA2701620C (en) 2014-12-09
AU2008308519B2 (en) 2014-09-11
JP5411145B2 (ja) 2014-02-12
EP2214666B1 (en) 2013-12-11
RU2490014C2 (ru) 2013-08-20
BRPI0817516A2 (pt) 2015-06-16
ES2449594T3 (es) 2014-03-20

Similar Documents

Publication Publication Date Title
MX2010013766A (es) Rasagilina para modificacion de enfermedad de parkinson.
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
NI201100100A (es) Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1.
WO2010088408A3 (en) Subunit selective nmda receptor antagonists for the treatment of neurological conditions
IL217901B (en) Use of laquinimod or a laquinimod salt in the manufacture of a drug for the treatment of bdnf-related diseases
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
MX2012009079A (es) Formulaciones de rasagilina de liberación prolongada y usos de las mismas.
NZ605469A (en) Nalbuphine-based formulations and uses thereof
RU2013154699A (ru) Сцилло-инозитол для применения в лечении поведенческих и психических расстройств
NZ593467A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
MY135838A (en) Methods for the treatment of mental disorders
WO2008011426A3 (en) Methods and medicaments for administration of ibuprofen
EA201171087A1 (ru) СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ
PL2111868T3 (pl) Zastosowanie ludzkiej albuminy do wytwarzania leku do leczenia pacjentów cierpiących na zaburzenia funkcji poznawczych
NZ576424A (en) Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
MX2011010732A (es) Pirimidinas sustituidas por imidazol utiles en el tratamiento de trastornos relacionados con glucogeno sintasa cinasa 3 como la enfermedad de alzheimer.
JP2013516493A5 (enExample)
SG141358A1 (en) Treatment of psychiatric patients with reduced heptaic function with paliperidone
DK1965797T3 (da) Nedsættelse af svimmelhed, en bivirkning forbundet med pirfenidonterapi
NZ593199A (en) Milnacipran for the long-term treatment of fybromyalgia syndrome
FI3188727T3 (fi) Tasimelteoni smith-magenisin oireyhtymän hoitamiseksi
NZ584729A (en) Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer
ATE506941T1 (de) Behandlung psychiatrischer patienten mit schlafstörungen und/oder übermässiger tagesschläfrigkeit mit paliperidon
MX366496B (es) Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 03 OCT 2015 BY HENRY HUGHES

Effective date: 20130416

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 OCT 2016 BY COMPUTER PACKAGES INC

Effective date: 20150918

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 OCT 2017 BY COMPUTER PACKAGES INC

Effective date: 20160920

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 OCT 2018 BY COMPUTER PACKAGES INC

Effective date: 20170920

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 OCT 2019 BY COMPUTER PACKAGES INC

Effective date: 20180918

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 OCT 2020 BY COMPUTER PACKAGES INC

Effective date: 20190918

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 OCT 2021 BY COMPUTER PACKAGES INC

Effective date: 20200918

LAPS Patent lapsed